|
Welcome
|
|
05 July 2008
|
|
|
| home | my details | ISRCTN Register | mRCT | UKCTG | links | information | press |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
| [ Print-friendly version ] |
| Breastfeeding duration and exclusivity: Impact on child health and development |
| ISRCTN | ISRCTN37687716 |
| ClinicalTrials.gov identifier | |
| Public title | Breastfeeding duration and exclusivity: Impact on child health and development |
| Scientific title | |
| Acronym | PROBIT |
| Serial number at source | MOP-53155 |
| Study hypothesis | Experimental intervention will lead to increased exclusivity and duration of breastfeeding, and hence to reduced infection and eczema in infancy. |
| Ethics approval | Ethics approval received from the Research Ethics Board of McGill University Health Centre on the 28th November 2001. |
| Study design | Randomised controlled trial |
| Countries of recruitment | Canada |
| Disease/condition/study domain | Healthy, full-term, breastfed infants |
| Participants - inclusion criteria |
1. Birth weight equal and above 2500 g, either sex
2. Gestational age equal and above 37 weeks 3. Maternal intention to breastfeed |
| Participants - exclusion criteria |
1. Neonatal disease or condition contraindicating breastfeeding
2. Neonatal disease or condition making breastfeeding difficult or impossible 3. Maternal psychosis 4. Maternal Human Immunodeficiency Virus (HIV) or active Tuberculosis (TB) 5. Maternal chemotherapy or radioisotopes |
| Anticipated start date | 01/04/2002 |
| Anticipated end date | 31/03/2008 |
| Status of trial | Completed |
| Patient information material | |
| Target number of participants | 17046 |
| Interventions |
Experimental group: breastfeeding promotion intervention at maternity hospitals and affiliated Polyclinics
Control group: continuation of maternity hospital and polyclinic practices existing at time of randomisation |
| Primary outcome measure(s) | One or more episodes of gastrointestinal infection in first 12 months of life. |
| Secondary outcome measure(s) |
1. Respiratory infections in first 12 months
2. Atopic eczema in first 12 months 3. Weight, length, and head circumference at 1, 2, 3, 6, 9, and 12 months 4. Blood Pressure (BP) at age 6.5 and 9 years 5. Asthma, hay fever, atopic eczema, and allergy skin tests at age 6.5 years 6. Intelligence Quotient (IQ) and behaviour at age 6.5 years 7. Oral/dental health at age 6.5 years 8. Lipids, lipoproteins, glucose, insulin, and HbA1c at age 9 years |
| Sources of funding |
1. Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MOP-53155)
2. United Nations Children's Fund (UNICEF) 3. Thrasher Research Fund (USA) 4. National Health Research and Development Program (NHRDP) - Health Canada (Canada) |
| Trial website | |
| Publications |
Results in:
1. http://www.ncbi.nlm.nih.gov/pubmed/17855282 2. http://www.ncbi.nlm.nih.gov/pubmed/18065591 3. http://www.ncbi.nlm.nih.gov/pubmed/18310164 4. http://www.ncbi.nlm.nih.gov/pubmed/18458209 |
| Contact name | Dr Michael S. Kramer |
| Address |
The Montreal Children's Hospital
2300 Tupper Street, T-118 |
| City/town | Montreal |
| Zip/Postcode | H3H 1P3 |
| Country | Canada |
| Tel | +1 514 4124400 ext. 22687 |
| Fax | +1 514 4124253 |
| michael.kramer@mcgill.ca | |
| Sponsor | McGill University (Canada) |
| Address |
845 Sherbrooke Street West
James Administration Bldg., Suite 429 |
| City/town | Montreal |
| Zip/Postcode | H3A 2T5 |
| Country | Canada |
| Date applied | 25/02/2005 |
| Last edited | 07/05/2008 |
| Date ISRCTN assigned | 09/09/2005 |
|
|
|
| © ISRCTN | |
|
|
|
|